While BTK inhibitors such as ibrutinib have been developed primarily for hematologic malignancies, the presence of a BTK mutation in ovarian cancer could open avenues for novel off-label therapeutic strategies, especially if further studies support the role of BTK in solid tumor metastasis. This evidence concerns the gene BTK and ovarian carcinoma.